Compare Lemonade Inc (LMND) vs GeneDx Holdings Corp (WGS) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Lemonade Inc vs GeneDx Holdings Corp — how do they compare? Lemonade Inc trades at $67.32 (market cap $5.18B), while GeneDx Holdings Corp trades at $60.64 (market cap $1.80B). The key difference: Lemonade Inc is far larger — about 2.9× GeneDx Holdings Corp's market cap, and Lemonade Inc is trading nearer its 52-week high, GeneDx Holdings Corp nearer its low. Which is the better fit depends on your goals.
| LMND | WGS | |
|---|---|---|
Market Cap | $5.18B | $1.80B |
Sector | Financials | Technology |
52-Week High | $96.57 | $167.51 |
52-Week Low | $36.28 | $34.51 |
Enterprise Value | $5.01B | $1.80B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Lemonade (LMND) trades at $67.47, up 0.43% on the day, with a bullish technical signal from moving averages and RSI near oversold levels. Revenue growth is accelerating, reaching $738 million in 2025, while net losses are narrowing to -$166 million. Recent news highlights expansion into new states and reinsurance program improvements, supporting optimism for future profitability.
The outlook is mixed: strong top-line growth and path to EBITDA positivity offer upside, but persistent losses and high valuation multiples pose risks. Analyst consensus targets $69.60, with 33% buy ratings, reflecting cautious optimism amid execution challenges in the competitive insurance sector.
GeneDx Holdings (WGS) trades at $60.65, down 4.46% amid a bearish technical signal and negative profitability. Recent earnings showed a Q1 2026 miss after two prior beats, with revenue growth but widening losses projected for 2026. The stock faces significant headwinds from multiple securities class action lawsuits alleging misrepresentations, with a deadline of August 3, 2026.
Despite a high analyst buy consensus (90.9%) and a $75.40 price target implying 24% upside, risks are elevated due to litigation, negative margins, and a high EV/EBITDA of 161.17. The upcoming Q2 2026 results on August 3 will be critical for investor confidence, but the legal overhang and fundamental challenges suggest cautious near-term outlook.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Lemonade Inc
Lemonade Inc operates in the insurance industry. The company offers digital and artificial intelligence based platform for various insurances and for settling claims and paying premiums. The platform ensures transparency in issuing policies and settling disputes.
Read more on LMND →About GeneDx Holdings Corp
GeneDx is a patient-centered health intelligence company that specializes in transforming healthcare through the application of genomics. It combines advanced technology with one of the world's largest rare disease genomic datasets to provide clinical-grade exome and genome sequencing, enabling precise and rapid diagnosis for patients with complex medical conditions.
Read more on WGS →
